<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724074</url>
  </required_header>
  <id_info>
    <org_study_id>garnett</org_study_id>
    <nct_id>NCT00724074</nct_id>
  </id_info>
  <brief_title>The Use of Continuous Wound Infusion Analgesia in Total Knee Arthroplasty</brief_title>
  <official_title>The Use of Continuous Wound Infusion Analgesia in Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Health, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Health, Canada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if there is improvement in pain and other&#xD;
      patient outcomes when using a continuous wound analgesia system after total knee replacement,&#xD;
      compared to usual methods of pain control. Another purpose is to determine if the system&#xD;
      makes it easier for nurses to care for these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous local wound infusion analgesia is a relatively new way of managing post-operative&#xD;
      pain, whereby a local anesthetic is continuously infused into the surgical area. Some studies&#xD;
      and users have reported decreased pain, decreased opioid use, decreased post-operative nausea&#xD;
      and vomiting, decreased length of stay, and improved patient and caregiver satisfaction with&#xD;
      the use of continuous local wound infusion analgesia, when compared to placebo, or usual&#xD;
      care, in arthroplasty and other surgical interventions.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      The On-Q PainBuster (continuous wound infusion analgesia) in TKA will result in improved&#xD;
      patient pain control, compared to usual care.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  Pain scores post-operatively will be better than usual care.&#xD;
&#xD;
        -  Fewer narcotics will be ingested post-operatively than with usual care.&#xD;
&#xD;
        -  Post-op nausea and vomiting will be less than usual care.&#xD;
&#xD;
        -  Length of stay will be shorter compared to usual care.&#xD;
&#xD;
        -  Patient satisfaction will be greater than satisfaction with usual care.&#xD;
&#xD;
        -  Post-operative infection rates will be no different between groups.&#xD;
&#xD;
        -  Fall rates will be no different between groups.&#xD;
&#xD;
        -  Subjects will participate in physical therapy the day of surgery.&#xD;
&#xD;
        -  Nursing Intensity requirements will be less with the wound infusion due to fewer&#xD;
           requests for pain medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain, measured by the 11-point numerical pain rating scale</measure>
    <time_frame>Post-operatively for three days then again at follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative nausea and vomiting</measure>
    <time_frame>Post-operatively for three days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic medications taken</measure>
    <time_frame>Post-operatively for three days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first mobilization, first transfer and first 30-M walk</measure>
    <time_frame>Up to three days post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Three days post-op (observed) then at follow-up (self-report)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Time of surgery to discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction (patient and caregiver)</measure>
    <time_frame>Discharge from hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care - post operative pain medications as per the knee arthroplasty care map.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>On-Q PainBuster with Bupivacaine</intervention_name>
    <description>On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic</description>
    <arm_group_label>S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual Care</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for TKA at the Royal Alexandra Hospital&#xD;
&#xD;
          -  Patient of Dr. Arnett&#xD;
&#xD;
          -  Deemed fit for continuous wound infusion (no allergies to Bupivacaine or related&#xD;
             medications) by anesthesia&#xD;
&#xD;
          -  Cognitively aware, and provides informed consent&#xD;
&#xD;
          -  Elective (not trauma-related) surgery&#xD;
&#xD;
          -  Able to read, speak and understand English&#xD;
&#xD;
          -  Adult &lt; 70 years of age&#xD;
&#xD;
          -  Intra-operative spinal anaesthesia&#xD;
&#xD;
          -  Reside within metropolitan Edmonton, in a bungalow&#xD;
&#xD;
          -  Have a caregiver at home&#xD;
&#xD;
          -  ASA risk classification of 1 or 2&#xD;
&#xD;
          -  Do not regularly use opioid medication pre-operatively&#xD;
&#xD;
          -  Have preoperative knee range of motion &gt; 90 degrees&#xD;
&#xD;
          -  Body Mass Index &lt; 40&#xD;
&#xD;
          -  No known hepatic or liver insufficiency&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Deemed unfit for continuous wound infusion due to allergies&#xD;
&#xD;
          -  Other exclusion criteria to be determined&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Arnett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital Health, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly Meyer, MSc</last_name>
    <phone>780-735-1119</phone>
    <email>holly.meyer@capitalhealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gordon Arnett, MD</last_name>
    <phone>780-455-5115</phone>
    <email>garnett@edmontonortho.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gordon Arnett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <last_update_submitted>July 25, 2008</last_update_submitted>
  <last_update_submitted_qc>July 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Gordon Arnett</name_title>
    <organization>Capital Health</organization>
  </responsible_party>
  <keyword>Arthritis of the knee</keyword>
  <keyword>Knee replacement</keyword>
  <keyword>Osteoarthritis, knee</keyword>
  <keyword>Arthroplasty, knee</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

